Core Viewpoint - Creative Medical Technology Holdings, Inc. has entered into agreements for the immediate exercise of existing warrants, which will generate approximately $3.7 million in gross proceeds for the company [1][3]. Group 1: Warrants and Financial Details - The company has agreements with certain warrant holders to exercise up to 837,104 shares at an exercise price of $4.42 per share, originally issued in October 2024 [1]. - In exchange for the immediate exercise of existing warrants, the company will issue new unregistered warrants for up to 1,674,208 shares at an exercise price of $3.75 per share, exercisable for five years after shareholder approval [2]. - The transaction is expected to close on or about March 6, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the warrant exercise will be utilized for working capital and general corporate purposes [3]. Group 3: Regulatory Information - The new warrants and the shares issuable upon their exercise are offered in a private placement and have not been registered under the Securities Act of 1933 [4]. - The company plans to file a registration statement with the SEC for the resale of shares issuable upon the exercise of the new warrants [4]. Group 4: Company Overview - Creative Medical Technology Holdings, Inc. is a biotechnology company focused on advancing novel biological therapeutics in various medical fields, including immunotherapy and orthopedics, and is listed on NASDAQ under the ticker symbol CELZ [6].

Core Insights - Creative Medical Technology Holdings, Inc. supports President Trump's executive order to expand access to in vitro fertilization (IVF), aligning with its OvaStem® program which shows an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient's own eggs [1][4] Group 1: Company Overview - Creative Medical Technology Holdings, Inc. is a biotechnology company focused on regenerative medicine, particularly in reproductive health through its OvaStem® program [1][5] - The company has filed for Orphan Drug Designation for Primary Ovarian Insufficiency (POI), highlighting its commitment to fertility innovation [2] Group 2: OvaStem® Program - OvaStem® offers a personalized alternative to traditional IVF by utilizing a patient's own cells, significantly improving the chances of conception for patients with POI, who typically have only a 5-10% chance of spontaneous pregnancy [2] - The next-generation OvaStem® integrates the AlloStem® platform, which is currently involved in two FDA-cleared clinical trials [2] Group 3: Executive Order Impact - The executive order mandates recommendations to lower out-of-pocket IVF costs, which currently range from $12,000 to $25,000 per cycle, potentially increasing access to advanced fertility technologies [3] - The administration's plan aims to remove financial barriers, facilitating greater adoption of fertility treatments [3] Group 4: Leadership Statements - The President and CEO of Creative Medical Technology Holdings expressed enthusiasm for the executive order, emphasizing the company's expertise in regenerative medicine and its potential to redefine reproductive health [4] - The Director of Clinical Operations highlighted the goal of providing safe, effective, and affordable infertility solutions, positioning OvaStem® at the forefront of this movement [4] Group 5: Future Commitment - Creative Medical Technology Holdings is committed to advancing innovative solutions in regenerative medicine, aiming to empower families and enhance shareholder value as federal efforts to expand fertility care progress [4]

Core Insights - Creative Medical Technology Holdings, Inc. supports President Trump's executive order aimed at expanding access to in vitro fertilization (IVF), aligning with the company's vision to enhance reproductive health through its OvaStem program, which shows an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient's own eggs, with no safety concerns reported up to five years post-treatment [1][4]. Group 1: OvaStem Program - OvaStem provides a novel, personalized alternative to traditional IVF for patients with Primary Ovarian Insufficiency (POI), who typically have only a 5-10% chance of spontaneous pregnancy and often rely on donor eggs [2]. - The next-generation OvaStem integrates the AlloStem platform, which is currently utilized in two FDA-cleared U.S. clinical trials, and the company has filed for Orphan Drug Designation for POI, reinforcing its leadership in fertility innovation [2]. Group 2: Executive Order Impact - The executive order mandates the Domestic Policy Council to deliver recommendations within 90 days to lower out-of-pocket IVF costs, which currently range from $12,000 to $25,000 per cycle, making treatment inaccessible for many families [3]. - By removing financial barriers, the administration's plan is expected to facilitate greater adoption of advanced fertility technologies [3]. Group 3: Company Commitment - The company expresses its commitment to providing the safest, most effective, and affordable infertility solutions, positioning OvaStem at the forefront of the fertility care revolution [4]. - With a robust portfolio of proprietary technologies and clinical programs, the company aims to address pressing medical challenges and drive shareholder value as federal efforts to expand fertility care progress [4].

Core Insights - Creative Medical Technology Holdings, Inc. announced positive mid-term follow-up data from its StemSpine® pilot study, which utilizes AlloStem™ cells for treating chronic lower back pain [1][2] Study Results - The pilot study showed a significant reduction in opioid dependency, with over 90% of patients reporting no opioid use for pain management three years post-procedure [2] - Pain scores decreased by 80%, and there was a greater than 60% improvement in Oswestry Disability Index scores [2] - Only one patient required reintervention at the three-year follow-up, and no serious adverse events were reported, indicating a favorable safety profile for the StemSpine® procedure [2] Technology Overview - StemSpine® is a patented, non-surgical, ultrasound-guided procedure that employs AlloStem™, an allogenic cell therapy developed by the company [3] - The patent for StemSpine® includes the use of both autologous and allogenic cells, enhancing its clinical applicability [3] Company Vision - The results highlight the safety and clinical efficacy of AlloStem™ in the StemSpine® procedure, promoting repair and improved vascularization in affected areas [4] - The company aims to provide innovative, non-surgical solutions for individuals suffering from chronic lower back pain [4] - The positive findings from the pilot study are expected to drive strong enrollment in the ongoing FDA-cleared Phase 1/2 ADAPT clinical trial for CELZ-201-DDT [4]

Core Insights - Creative Medical Technology Holdings, Inc. announced promising one-year follow-up data from the AlloStem (CELZ-201) pilot study for late-stage Type 2 Diabetes, demonstrating significant efficacy and safety [1][2][3] Study Results - CELZ-201 achieved an 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels, with no serious adverse effects reported [2][3] - The study involved 20 patients, with 10 receiving CELZ-201 and 10 undergoing optimized medical therapy, validating the safety and efficacy of CELZ-201 [3] Future Development Plans - The company plans to advance the development of AlloStem (CELZ-201) for late-stage Type 2 Diabetes and explore other potential applications to expand its pipeline [4] - The positive data represents a significant milestone in the company's mission to revolutionize diabetes treatment [5] Company Overview - Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company focused on developing regenerative cell therapies targeting various conditions, including endocrinology and immunotherapy [7]

Core Insights - Creative Medical Technology Holdings, Inc. has announced an expanded agreement with Greenstone Biosciences to utilize Artificial Intelligence in the development of its human induced pluripotent stem cell platform for diabetes treatment [1][2]. Group 1: Strategic Collaboration - The collaboration aims to enhance Creative Medical's hypoimmune iPSC technology, particularly its iPSC-derived pancreatic islet cells, which are currently in clinical trials [2]. - The integration of AI-driven drug discovery is expected to identify small molecules that improve insulin secretion, thereby refining the therapeutic potential of the iPSC-derived pancreatic islet cells [2][3]. - The program will also focus on multi-gene editing to create next-generation hypoimmune iPSC lines with improved stealth, survival, and differentiation capabilities [2][6]. Group 2: Addressing Clinical Challenges - A major challenge in stem cell therapies is the need for immunosuppression, which can cause severe side effects. Creative Medical aims to overcome this by refining hypoimmune iPSC lines through AI-guided development [3][6]. - The advancements in multi-gene edited hypoimmune iPSCs could eliminate the need for immunosuppression, significantly enhancing patient outcomes in regenerative therapies [6]. Group 3: Leadership and Vision - The President and CEO of Creative Medical emphasized that the partnership with Greenstone represents a significant milestone in the company's mission to develop transformative therapies [4]. - The incorporation of AI methodologies is projected to reduce R&D time by approximately 50% and generate millions of dollars in cost savings, positioning the company as a leader in personalized medicine [5]. Group 4: Company Overview - Creative Medical Technology Holdings, Inc. is focused on developing innovative regenerative therapies using stem cell and immune modulation technologies, targeting conditions such as diabetes, autoimmune disorders, and neurological diseases [8].

Core Insights - Creative Medical Technology Holdings, Inc. announced promising initial data from its Phase 1/2 clinical trial of CELZ-201-DDT, a stem cell-based therapy for chronic back pain due to degenerative disc disease [1][2] - The first cohort of 10 participants completed the study without any dose-limiting toxicities or serious adverse events, indicating a strong safety profile [2][8] - Preliminary blinded data suggests potential therapeutic benefits in alleviating back pain and restoring functionality, leading to the recommendation from the Data Safety Monitoring Board (DSMB) to proceed to the next cohort [2][8] Company Commitment - The company emphasizes its commitment to addressing chronic back pain, a condition with limited effective treatment options, and believes CELZ-201-DDT could transform the standard of care for patients [4][5] - CELZ-201-DDT aims to leverage stem cell technology to address the root causes of pain and degenerative conditions, providing a novel, non-opioid therapeutic option [4][5] Study Design and Future Plans - The Phase 1/2 study is designed to evaluate the safety, efficacy, and tolerability of CELZ-201-DDT, with plans to enroll 30 individuals suffering from chronic lower back pain [6][8] - Enrollment for the second cohort is expected in the first quarter of 2025, with comprehensive data from subsequent cohorts guiding future clinical and regulatory plans [8]

Core Insights - Creative Medical Technology Holdings, Inc. has successfully completed an independent interim safety review for its ADAPT clinical trial evaluating CELZ-201, a novel therapeutic product for chronic lower back pain [1][2][3] - The Data Safety Monitoring Board (DSMB) concluded that the trial may proceed, highlighting the safety profile of CELZ-201 and supporting its advancement [2][3] - The ADAPT trial is a double-blind, randomized, placebo-controlled, dose-escalation study designed to assess the safety, tolerability, and efficacy of CELZ-201 [3][4] Company Overview - Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company focused on regenerative medicine therapies derived from adult stem cells [5] - The company aims to develop targeted cellular therapies to address unmet medical needs, particularly in degenerative diseases [4][5] - CELZ-201 represents the company's commitment to delivering transformative treatments for patients suffering from chronic conditions [4][5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of Registrant as specified in its charter) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of Registrant as specified in its charter) | --- ...